Galderma initiates two new clinical trials investigating nemolizumab in patients with Systemic Sclerosis and Chronic Pruritus of Unknown Origin Press release
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership Press release
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years Press release
RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years Press release
Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering Press release
Galderma intends to buy back approximately 2.4 million shares in the context of the accelerated bookbuild offering by EQT, ADIA and Auba Press release
Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance Press release
Galderma launches "Scratch Resistance" campaign to validate the physical and emotional burdens of atopic dermatitis Press release
Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology® Press release
